Evidence map›Paper›PMID 42299352›Full record

ArticleBiochemia medica2026

Cross-interference of hemolysis, icterus and lipemia: A study with real patient samples.

Hatice Bozkurt Yavuz, Soycan Tüner

Abstract read
In one paragraph

Article in Biochemia medica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hatice Bozkurt YavuzDepartment of Clinical Chemistry, Uşak University Faculty of Medicine, Uşak, Turkey.
Soycan TünerDepartment of Clinical Chemistry, Uşak University Faculty of Medicine, Uşak, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hemolysis, icterus, and lipemia (HIL) are frequent preanalytical interferences, leading to erroneous results or sample rejection. While individual effects of these indices have been studied, their interferences on each other remain largely unexplored. This study aimed to evaluate the cross-interference of HIL parameters using endogenous patient-derived samples, thereby ensuring clinically relevant conditions, and to propose a decision algorithm for improved sample quality assessment. Materials and methods: Following the CLSI-EP07 guideline, high-concentration icterus and lipemia pools from leftover clinical samples and hemolizate pool have been prepared. These pools were serially diluted with low-index serum (HIL0) to obtain defined combinations. Indices were measured using the Abbott Alinity c system. Cross interferences were calculated as percentage bias compared to baseline values. Results: High level hemolysis remained largely unaffected by other indices. Hemolysis in the range of 2.5-10.0 g/L caused a 20-150% false increase in lipemia and a 10-60% false decrease in icterus. Conversely, lipemia in the range of 25-100 index led to a 20-150% false increase in icterus and reduced low level of hemolysis by 10-30%. Similarly, icterus at 42.75-171 µmol/L resulted in a 15-45% false reduction in low levels of hemolysis. No concentration-dependent systematic bias was observed for lipemia and icterus, whereas hemolysis showed level-dependent effects. Conclusions: Cross-interference among HIL indices can lead to misinterpretation if indices are assessed independently. A rule-based, threshold-dependent algorithm incorporating these interactions is proposed to enhance accuracy in sample rejection decisions. Implementation of such integrated approaches, along with manufacturer transparency may significantly improve laboratory reliability.

Indexed as

HemolysisHyperlipidemiasJaundiceHumanshemolysisicterusinterferencelipemiapreanalytical phasesample handling

Identifiers

PMID42299352
PMCPMC13262756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.